BNTC — Benitec Biopharma Ltd ADR
NASDAQ · Healthcare · Biotechnology
$12.31
+$0.14 (+1.15%)
Benitec Biopharma Ltd ADR (BNTC) is a biotechnology company listed on NASDAQ. It is led by Jerel A. Banks M.D., Ph.D., based in 3940 Trust Way, Hayward, CA, United States, 94545, with about 19 employees. Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Latest reported BNTC revenue for 2025-09-30 was $0. Net income was -$9.0M. BNTC currently screens at market cap $388.7M.
Use this BNTC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BNTC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BNTC SEC filings page. Lician reads the product cache first so this HTML stays unique to Benitec Biopharma Ltd ADR even when a live quote feed is slow.
About Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
BNTC Key Statistics
Market Cap
$388.72M
Volume
127,780
Previous Close
$12.71
Day Range
$12.79 – $13.35
P/B Ratio
2.08
EPS
-$0.21
Revenue
$0.00
Net Income
-$8.80M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
19
BNTC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.80M | -$5.06M | -$19.56M |
| EPS (Diluted) | -$0.21 | -$0.18 | -$14.12 |
Total Assets
$99.59M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$72.80M
Operating Cash Flow
-$23.59M
Free Cash Flow
$0.00
Benitec Biopharma Ltd ADR Company Information
- Executive Chairman & CEO
- Jerel A. Banks M.D., Ph.D.
- Headquarters
- 3940 Trust Way, Hayward, CA, United States, 94545
- Website
- benitec.com
- Phone
- 510 780 0819
- IPO / Founded
- 2015-08-18
- Sector
- Healthcare
- Industry
- Biotechnology